Prognostic Biomarkers for Melanoma Immunotherapy
نویسندگان
چکیده
منابع مشابه
Prognostic Biomarkers in Melanoma
Biomarkers are tumouror host-related factors that correlate with tumour biological behaviour and patient prognosis. Modern analytical techniques have identified numerous possible biomarkers, but their relevance to melanoma progression, clinical outcome and the selection of optimal treatment strategies still needs to be established. In this review, we discuss common predictive biomarkers of mela...
متن کاملStage-specific prognostic biomarkers in melanoma
The melanoma staging system proposed by the American Joint Committee on Cancer (AJCC) (which classifies melanoma patients into four clinical stages) is currently the most widely used tool for melanoma prognostication, and clinical management decision making by clinicians. However, multiple studies have shown that melanomas within specific AJCC Stages can exhibit varying progression and clinical...
متن کاملPrognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma
Prognosis and survival for malignant melanoma is highly dependent on early diagnosis and treatment. While the American Joint Committee on Cancer (AJCC) criterion provides a means of staging melanomas and guiding treatment approaches, it is unable to identify the risk of disease progression of early stage tumors or provide reliable stratification for novel adjuvant therapies. The demand for cred...
متن کاملCombination Immunotherapy for Melanoma.
Advances in precisionmedicine and immunology have led tomajor paradigmshifts in thegeneral approach to treatingpatientswith metastatic cancer. This is perhaps best exemplified by malignant melanoma, an aggressive tumor characterized by alterations in definedcell signalingpathwaysandsusceptibility to recognitionby the immunesystem.Over thepast4years, therehavebeen7newdrugs approved by the US Foo...
متن کاملImmunotherapy for melanoma.
BACKGROUND Immunotherapy for cancers is based on the principle that the host's immune system is capable of generating immune responses against tumor cells. Currently available treatments for melanoma patients are limited by poor response rates. Interferon-a has been approved for adjuvant treatment of stage III melanoma with improved survival. New and more innovative approaches with improved eff...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology Reports
سال: 2020
ISSN: 1523-3790,1534-6269
DOI: 10.1007/s11912-020-0886-z